M&A
Karyopharm files Chapter 11, names Ayrmid as lead bidder in planned merger
Key Facts
Signal Type
M&A
Industry
Biotech
Companies
Karyopharm Therapeutics, Ayrmid, Gamida Cell, Incyte
Date
Karyopharm Therapeutics, the Massachusetts-based maker of multiple myeloma drug Xpovio, filed for Chapter 11 bankruptcy as part of a plan to merge with Irish hematology biotech Ayrmid. Ayrmid — parent company of blood cancer biotech Gamida Cell — is named lead bidder in a court-supervised sale of Karyopharm's assets, though the terms of its offer were not disclosed and the merger is not final.
The bidding structure, if approved by the court, allows other parties to submit competing proposals, an approach Karyopharm says is designed to maximize value for stakeholders. The transaction is expected to close in the first quarter of 2027. Karyopharm also secured commitments for up to $55 million in debtor-in-possession financing from its existing lenders, subject to court approval, which it says combined with Xpovio revenue will fund operations through the Chapter 11 process.
Karyopharm retains its commercial product Xpovio and its multiple myeloma and myelofibrosis pipeline through the restructuring. Xpovio posted $30.8 million in second-quarter sales, up slightly from $29.7 million a year earlier, but annual sales have stayed flat between $112 million and $115 million since 2023. The company has already cut staff by 20% in 2023 and another 20% last year.
Ayrmid brings two FDA-approved products — cell therapy Omisirge and Aphexda, approved in 2023 for stem cell retrieval in multiple myeloma — and its chairman and CEO Joe Wiley cited "complementary portfolios, established commercial capabilities and a shared commitment" to hematology. Incyte is also in the frame: in August, Karyopharm applied for FDA accelerated approval of Xpovio in combination with Incyte's Jakafi for myelofibrosis patients.
The filing caps a difficult year that included a Phase 3 myelofibrosis miss in March, the FDA's May rescission of Xpovio's accelerated approval in relapsed or refractory DLBCL, and a failed endometrial cancer Phase 3 in July that sent shares down more than 68%. That sequence, plus a cash runway leadership said in August covered only another month, is what forced the sale process.
Court approval of the bidding procedures and the $55 million DIP facility is the first gate — without it, the timeline and the financing both slip. Watch for competing bids ahead of the auction, since Karyopharm explicitly structured the process to invite them, and for any change to the Q1 2027 close target.
On the commercial side, track the FDA accelerated approval filing for Xpovio plus Jakafi in myelofibrosis and whether Xpovio revenue holds near $30 million per quarter through the Chapter 11. Any further pipeline setback or prescriber disruption would weaken the asset case Ayrmid is underwriting.
Source:
Fierce BiotechGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
